AR116604A1 - Inhibidores de kras g12c - Google Patents

Inhibidores de kras g12c

Info

Publication number
AR116604A1
AR116604A1 ARP190102837A ARP190102837A AR116604A1 AR 116604 A1 AR116604 A1 AR 116604A1 AR P190102837 A ARP190102837 A AR P190102837A AR P190102837 A ARP190102837 A AR P190102837A AR 116604 A1 AR116604 A1 AR 116604A1
Authority
AR
Argentina
Prior art keywords
formula
compounds
kras
inhibitors
pharmaceutically acceptable
Prior art date
Application number
ARP190102837A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR116604A1 publication Critical patent/AR116604A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente proporciona compuestos de la fórmula (1) a continuación, en donde R¹, R² y m son como se describan en la presente, sales aceptables desde el punto de vista farmacéutico de los compuestos de fórmula (1), y métodos para usar estos compuestos y sales para tratar pacientes con cáncer. Reivindicación 1: Un compuesto de la fórmula (1), en donde m es 0 - 2; cada R¹ es F; y R² se selecciona de: H, F y CI; o una sal de este aceptable desde el punto de vista farmacéutico.
ARP190102837A 2018-10-15 2019-10-04 Inhibidores de kras g12c AR116604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862745502P 2018-10-15 2018-10-15

Publications (1)

Publication Number Publication Date
AR116604A1 true AR116604A1 (es) 2021-05-26

Family

ID=68318975

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102837A AR116604A1 (es) 2018-10-15 2019-10-04 Inhibidores de kras g12c

Country Status (8)

Country Link
US (1) US10968214B2 (es)
EP (1) EP3867251B1 (es)
JP (1) JP6824475B1 (es)
CN (1) CN112805281B (es)
AR (1) AR116604A1 (es)
ES (1) ES2927980T3 (es)
TW (1) TW202033518A (es)
WO (1) WO2020081282A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7451419B2 (ja) 2018-10-26 2024-03-18 大鵬薬品工業株式会社 新規なインダゾール化合物又はその塩
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CR20220230A (es) 2019-10-28 2022-06-15 Merck Sharp & Dohme Inhibidores de pequeñas moléculas de mutante g12c de kras
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
UA128806C2 (uk) 2019-12-11 2024-10-23 Елі Ліллі Енд Компані Інгібітори kras g12c
KR20230019101A (ko) * 2020-04-29 2023-02-07 상하이 린진 바이오파마 씨오., 엘티디. 벤조티아졸릴 비아릴 화합물, 제조 방법 및 용도
CA3183032A1 (en) 2020-06-18 2021-12-23 Mallika Singh Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
CN113880827B (zh) * 2020-07-03 2024-10-01 苏州闻天医药科技有限公司 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
EP4203952A4 (en) * 2020-08-28 2024-12-11 Kumquat Biosciences Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2022087371A1 (en) * 2020-10-22 2022-04-28 Spectrum Pharmaceuticals, Inc. Novel bicyclic compounds
CN114920738B (zh) * 2020-11-06 2025-07-29 泰励生物科技（上海）有限公司 用于癌症治疗的KRas抑制剂
CN120887884A (zh) 2020-11-06 2025-11-04 泰励生物科技（上海）有限公司 用于癌症治疗的KRas抑制剂
TWI880049B (zh) 2020-12-04 2025-04-11 美商美國禮來大藥廠 Kras g12c抑制劑
JP7637777B2 (ja) * 2020-12-08 2025-02-28 ジェネンテック， インコーポレイテッド 固形腫瘍を治療するためのｋｒａｓｇ１２ｃ阻害剤及びｅｇｆｒ阻害剤を含む方法及び組成物
JP2024517693A (ja) * 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド ２－アミノベンゾチアゾール化合物及びその使用方法
CN117500799A (zh) * 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
IL310291A (en) 2021-07-23 2024-03-01 Theras Inc Compositions and methods for inhibition of ras
TW202327569A (zh) 2021-09-01 2023-07-16 瑞士商諾華公司 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途
AU2022371727A1 (en) 2021-10-22 2024-05-02 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
US20250177389A1 (en) 2022-03-04 2025-06-05 Eli Lilly And Company Method of treatment including kras g12c inhibitors and shp2 inhibitors
JP2025508133A (ja) 2022-03-11 2025-03-21 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
JP7676677B2 (ja) 2022-03-25 2025-05-14 イーライ リリー アンド カンパニー Ｋｒａｓ阻害剤
EP4504209A1 (en) 2022-04-08 2025-02-12 Eli Lilly and Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
WO2024031088A1 (en) 2022-08-05 2024-02-08 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024061353A1 (zh) * 2022-09-23 2024-03-28 南京明德新药研发有限公司 喹唑啉类化合物的晶型及其制备方法
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CN121079301A (zh) 2023-03-30 2025-12-05 伊莱利利公司 Kras抑制剂
TWI901059B (zh) 2023-03-31 2025-10-11 美商美國禮來大藥廠 Kras抑制劑
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025072457A1 (en) 2023-09-27 2025-04-03 Eli Lilly And Company Kras inhibitors
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026035947A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
EP3636639A1 (en) * 2013-10-10 2020-04-15 Araxes Pharma LLC Inhibitors of kras g12c
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos

Also Published As

Publication number Publication date
EP3867251A1 (en) 2021-08-25
WO2020081282A1 (en) 2020-04-23
JP2021505640A (ja) 2021-02-18
ES2927980T3 (es) 2022-11-14
EP3867251B1 (en) 2022-09-07
US20200115375A1 (en) 2020-04-16
CN112805281B (zh) 2022-05-10
JP6824475B1 (ja) 2021-02-03
CN112805281A (zh) 2021-05-14
TW202033518A (zh) 2020-09-16
US10968214B2 (en) 2021-04-06

Similar Documents

Publication Publication Date Title
AR116604A1 (es) Inhibidores de kras g12c
CO2022008091A2 (es) Inhibidores de kras g12c
AR122783A2 (es) Inhibidores de kras g12c y métodos para su uso
AR132295A1 (es) Inhibidores de kras
AR132294A1 (es) Inhibidores de kras
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
CR20190124A (es) Inhibidores de ssao de aminopirimidina
AR114803A1 (es) Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
MX2021011606A (es) Compuestos dirigidos a prmt5.
CO2020000194A2 (es) Inhibidores de quinasa alk2 que contienen imidazol
CL2021003202A1 (es) Compuestos de pirrolidina
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA202193015A1 (ru) Ингибиторы cdk
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CO2024001367A2 (es) Compuestos antivirales
AR133985A1 (es) Inhibidores de kras
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
PE20212070A1 (es) Moduladores de trex1
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
CO2021017202A2 (es) Compuestos tricíclicos
CO2021014210A2 (es) Compuestos de pirrol
AR096148A1 (es) Terapia combinada para el tratamiento del cáncer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal